Do analysts prefer GRVY or OPRX?

OptimizeRx has a consensus price target of $13.43, suggesting a potential upside of 195.78%. Given OptimizeRx's stronger consensus rating and higher probable upside, analysts plainly believe OptimizeRx is more favorable than GRAVITY. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRAVITY 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 OptimizeRx 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56

Which has preferable earnings and valuation, GRVY or OPRX?

GRAVITY has higher revenue and earnings than OptimizeRx. GRAVITY is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAVITY $388.04M 1.25 $47.22M $7.30 9.56 OptimizeRx $109.43M 0.78 $5.13M $0.35 12.97

Is GRVY or OPRX more profitable?

GRAVITY has a net margin of 12.63% compared to OptimizeRx's net margin of 6.37%. GRAVITY's return on equity of 11.44% beat OptimizeRx's return on equity. Company Net Margins Return on Equity Return on Assets GRAVITY 12.63% 11.44% 9.68% OptimizeRx 6.37% 10.86% 7.93%

Does the media favor GRVY or OPRX?

In the previous week, GRAVITY and GRAVITY both had 1 articles in the media. OptimizeRx's average media sentiment score of 1.27 beat GRAVITY's score of -0.11 indicating that OptimizeRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAVITY 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral OptimizeRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, OPRX or PAYS?

Paysign has lower revenue, but higher earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Paysign, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OptimizeRx $109.43M 0.78 $5.13M $0.35 12.97 Paysign $82.03M 5.07 $7.55M $0.17 43.76

Is OPRX or PAYS more profitable?

Paysign has a net margin of 11.38% compared to OptimizeRx's net margin of 6.37%. Paysign's return on equity of 21.74% beat OptimizeRx's return on equity. Company Net Margins Return on Equity Return on Assets OptimizeRx 6.37% 10.86% 7.93% Paysign 11.38% 21.74% 4.19%

Does the media prefer OPRX or PAYS?

In the previous week, OptimizeRx and OptimizeRx both had 1 articles in the media. OptimizeRx's average media sentiment score of 1.27 beat Paysign's score of 0.05 indicating that OptimizeRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OptimizeRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Paysign 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, OPRX or RMNI?

Rimini Street has higher revenue and earnings than OptimizeRx. Rimini Street is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OptimizeRx $109.43M 0.78 $5.13M $0.35 12.97 Rimini Street $421.54M 0.92 $37.10M $0.37 11.27

Does the media prefer OPRX or RMNI?

In the previous week, Rimini Street had 1 more articles in the media than OptimizeRx. MarketBeat recorded 2 mentions for Rimini Street and 1 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 1.27 beat Rimini Street's score of 0.86 indicating that OptimizeRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OptimizeRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rimini Street 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, GLOO or OPRX?

OptimizeRx has higher revenue and earnings than Gloo. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gloo $94.66M 3.98 N/A N/A N/A OptimizeRx $109.43M 0.78 $5.13M $0.35 12.97

Is GLOO or OPRX more profitable?

OptimizeRx has a net margin of 6.37% compared to Gloo's net margin of 0.00%. OptimizeRx's return on equity of 10.86% beat Gloo's return on equity. Company Net Margins Return on Equity Return on Assets Gloo N/A N/A N/A OptimizeRx 6.37% 10.86% 7.93%

Does the media refer more to GLOO or OPRX?

In the previous week, Gloo had 8 more articles in the media than OptimizeRx. MarketBeat recorded 9 mentions for Gloo and 1 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 1.27 beat Gloo's score of -0.14 indicating that OptimizeRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gloo 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OptimizeRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, OPRX or TSSI?

TSS has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than TSS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OptimizeRx $109.43M 0.78 $5.13M $0.35 12.97 TSS $202.11M 1.77 $15.12M $0.49 25.96

Is OPRX or TSSI more profitable?

TSS has a net margin of 7.14% compared to OptimizeRx's net margin of 6.37%. TSS's return on equity of 25.27% beat OptimizeRx's return on equity. Company Net Margins Return on Equity Return on Assets OptimizeRx 6.37% 10.86% 7.93% TSS 7.14% 25.27% 8.97%

Does the media prefer OPRX or TSSI?

In the previous week, TSS had 1 more articles in the media than OptimizeRx. MarketBeat recorded 2 mentions for TSS and 1 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 1.27 beat TSS's score of 0.00 indicating that OptimizeRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OptimizeRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TSS 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

OptimizeRx (OPRX) Competitors

$4.54 -0.14 (-2.99%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$4.60 +0.06 (+1.30%)

As of 06/23/2026 06:39 PM Eastern

Compare

OPRX vs. GRVY, PAYS, RMNI, GLOO, and TSSI

Should you buy OptimizeRx stock or one of its competitors? MarketBeat compares OptimizeRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OptimizeRx include GRAVITY (GRVY), Paysign (PAYS), Rimini Street (RMNI), Gloo (GLOO), and TSS (TSSI). These companies are all part of the "business services" industry.

How does OptimizeRx compare to GRAVITY?

GRAVITY (NASDAQ:GRVY) and OptimizeRx (NASDAQ:OPRX) are both small-cap computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

9.9% of GRAVITY shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 7.5% of OptimizeRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, GRAVITY and GRAVITY both had 1 articles in the media. OptimizeRx's average media sentiment score of 1.27 beat GRAVITY's score of -0.11 indicating that OptimizeRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAVITY	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
OptimizeRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OptimizeRx has a consensus price target of $13.43, suggesting a potential upside of 195.78%. Given OptimizeRx's stronger consensus rating and higher probable upside, analysts plainly believe OptimizeRx is more favorable than GRAVITY.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAVITY	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

GRAVITY has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, OptimizeRx has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

GRAVITY has higher revenue and earnings than OptimizeRx. GRAVITY is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAVITY	$388.04M	1.25	$47.22M	$7.30	9.56
OptimizeRx	$109.43M	0.78	$5.13M	$0.35	12.97

GRAVITY has a net margin of 12.63% compared to OptimizeRx's net margin of 6.37%. GRAVITY's return on equity of 11.44% beat OptimizeRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAVITY	12.63%	11.44%	9.68%
OptimizeRx	6.37%	10.86%	7.93%

Summary

OptimizeRx beats GRAVITY on 8 of the 15 factors compared between the two stocks.

How does OptimizeRx compare to Paysign?

OptimizeRx (NASDAQ:OPRX) and Paysign (NASDAQ:PAYS) are both small-cap business services companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

OptimizeRx has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Paysign has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

In the previous week, OptimizeRx and OptimizeRx both had 1 articles in the media. OptimizeRx's average media sentiment score of 1.27 beat Paysign's score of 0.05 indicating that OptimizeRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Paysign	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OptimizeRx currently has a consensus price target of $13.43, suggesting a potential upside of 195.78%. Paysign has a consensus price target of $10.00, suggesting a potential upside of 34.41%. Given OptimizeRx's higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than Paysign.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Paysign	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Paysign has lower revenue, but higher earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Paysign, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	0.78	$5.13M	$0.35	12.97
Paysign	$82.03M	5.07	$7.55M	$0.17	43.76

76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 25.9% of Paysign shares are held by institutional investors. 7.5% of OptimizeRx shares are held by insiders. Comparatively, 24.5% of Paysign shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Paysign has a net margin of 11.38% compared to OptimizeRx's net margin of 6.37%. Paysign's return on equity of 21.74% beat OptimizeRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	6.37%	10.86%	7.93%
Paysign	11.38%	21.74%	4.19%

Summary

OptimizeRx beats Paysign on 8 of the 15 factors compared between the two stocks.

How does OptimizeRx compare to Rimini Street?

OptimizeRx (NASDAQ:OPRX) and Rimini Street (NASDAQ:RMNI) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, Rimini Street had 1 more articles in the media than OptimizeRx. MarketBeat recorded 2 mentions for Rimini Street and 1 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 1.27 beat Rimini Street's score of 0.86 indicating that OptimizeRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rimini Street	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rimini Street has higher revenue and earnings than OptimizeRx. Rimini Street is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	0.78	$5.13M	$0.35	12.97
Rimini Street	$421.54M	0.92	$37.10M	$0.37	11.27

OptimizeRx has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Rimini Street has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 73.8% of Rimini Street shares are held by institutional investors. 7.5% of OptimizeRx shares are held by insiders. Comparatively, 42.0% of Rimini Street shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Rimini Street has a net margin of 8.30% compared to OptimizeRx's net margin of 6.37%. OptimizeRx's return on equity of 10.86% beat Rimini Street's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	6.37%	10.86%	7.93%
Rimini Street	8.30%	-24.30%	1.64%

OptimizeRx presently has a consensus target price of $13.43, suggesting a potential upside of 195.78%. Rimini Street has a consensus target price of $5.50, suggesting a potential upside of 31.89%. Given OptimizeRx's stronger consensus rating and higher possible upside, equities research analysts clearly believe OptimizeRx is more favorable than Rimini Street.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Rimini Street	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

OptimizeRx and Rimini Street tied by winning 8 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to Gloo?

Gloo (NASDAQ:GLOO) and OptimizeRx (NASDAQ:OPRX) are both small-cap business services companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

76.5% of OptimizeRx shares are held by institutional investors. 45.2% of Gloo shares are held by company insiders. Comparatively, 7.5% of OptimizeRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

OptimizeRx has higher revenue and earnings than Gloo.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gloo	$94.66M	3.98	N/A	N/A	N/A
OptimizeRx	$109.43M	0.78	$5.13M	$0.35	12.97

OptimizeRx has a net margin of 6.37% compared to Gloo's net margin of 0.00%. OptimizeRx's return on equity of 10.86% beat Gloo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gloo	N/A	N/A	N/A
OptimizeRx	6.37%	10.86%	7.93%

Gloo presently has a consensus target price of $16.00, suggesting a potential upside of 248.58%. OptimizeRx has a consensus target price of $13.43, suggesting a potential upside of 195.78%. Given Gloo's higher possible upside, equities research analysts plainly believe Gloo is more favorable than OptimizeRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gloo	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Gloo had 8 more articles in the media than OptimizeRx. MarketBeat recorded 9 mentions for Gloo and 1 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 1.27 beat Gloo's score of -0.14 indicating that OptimizeRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gloo	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OptimizeRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

OptimizeRx beats Gloo on 8 of the 12 factors compared between the two stocks.

How does OptimizeRx compare to TSS?

OptimizeRx (NASDAQ:OPRX) and TSS (NASDAQ:TSSI) are both small-cap business services companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

TSS has a net margin of 7.14% compared to OptimizeRx's net margin of 6.37%. TSS's return on equity of 25.27% beat OptimizeRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	6.37%	10.86%	7.93%
TSS	7.14%	25.27%	8.97%

In the previous week, TSS had 1 more articles in the media than OptimizeRx. MarketBeat recorded 2 mentions for TSS and 1 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 1.27 beat TSS's score of 0.00 indicating that OptimizeRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TSS	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OptimizeRx presently has a consensus price target of $13.43, indicating a potential upside of 195.78%. TSS has a consensus price target of $17.17, indicating a potential upside of 34.96%. Given OptimizeRx's stronger consensus rating and higher probable upside, research analysts clearly believe OptimizeRx is more favorable than TSS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
TSS	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

OptimizeRx has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, TSS has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market.

TSS has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than TSS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	0.78	$5.13M	$0.35	12.97
TSS	$202.11M	1.77	$15.12M	$0.49	25.96

76.5% of OptimizeRx shares are owned by institutional investors. 7.5% of OptimizeRx shares are owned by insiders. Comparatively, 16.0% of TSS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

TSS beats OptimizeRx on 11 of the 16 factors compared between the two stocks.

Get OptimizeRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OPRX vs. The Competition

Export

Metric	OptimizeRx	COMP Industry	Computer Sector	NASDAQ Exchange
Market Cap	$87.82M	$128.37B	$39.35B	$12.39B
Dividend Yield	N/A	2.18%	3.27%	5.83%
P/E Ratio	12.97	19.40	169.90	23.98
Price / Sales	0.78	4.48	624.23	109.07
Price / Cash	4.76	16.08	48.53	54.51
Price / Book	0.66	30.49	9.58	6.50
Net Income	$5.13M	$5.27B	$1.07B	$336.88M
7 Day Performance	-10.63%	-1.71%	-0.80%	-0.14%
1 Month Performance	-8.10%	-7.70%	0.99%	0.77%
1 Year Performance	-64.81%	-22.58%	156.70%	28.49%

OptimizeRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OPRX OptimizeRx	4.7675 of 5 stars	$4.54 -3.0%	$13.43 +195.8%	-65.0%	$87.82M	$109.43M	12.97	100	Positive News High Trading Volume
GRVY GRAVITY	0.8227 of 5 stars	$57.29 +1.3%	N/A	+12.6%	$398.54M	$388.04M	7.86	340	Positive News
PAYS Paysign	4.4947 of 5 stars	$7.08 +1.6%	$10.00 +41.2%	+26.1%	$396.57M	$82.03M	41.72	80	News Coverage
RMNI Rimini Street	4.6131 of 5 stars	$4.19 +0.4%	$5.50 +31.4%	+32.8%	$387.36M	$421.54M	11.31	1,980	Positive News
GLOO Gloo	3.0102 of 5 stars	$4.51 -2.3%	$16.00 +254.6%	N/A	$369.17M	$94.66M	N/A	550	Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OPRX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OptimizeRx (OPRX) Competitors